---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219801"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-05-12T21:07:04+00:00"
generated_at: "2026-05-12T21:21:26.161529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BBOT Q1 net loss widens to $42.1M; cash $388.9M funds ops into 2028; pipeline shows early efficacy

## Summary
- Net loss $42.1M vs $22.1M YoY; R&D spend $39.8M on advancing three RAS programs.
- Cash, equivalents and marketable securities $388.9M as of March 31, 2026; runway into 2028.
- BBO-8520 monotherapy ORR 65% in KRAS G12C NSCLC; BBO-11818 partial response in pancreatic cancer.
- BBO-10203 achieved target engagement with no hyperglycemia; clinical benefit in CRC and HR+ BC.
- Pedro Beltran appointed CEO, Idan Elmelech COO effective April 20, 2026; Neil Kumar Executive Chairman.

## SEC filing metadata
- accession: 0001193125-26-219801
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-05-12T21:07:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/0001193125-26-219801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/bbot-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219801
- JSON: https://secwatch.observer/filing/0001193125-26-219801.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219801.txt

## Key facts
- Earnings Releases
  BridgeBio Oncology Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $42.1 million for the first quarter of 2026 compared to $22.1 million for the first qu.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss was $42.1 million for the first quarter of 2026 compared to $22.1 million for the first qu
  - Result: reported results
  source text: BridgeBio Oncology Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526219801/0001193125-26-219801-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.